Fraser McIntosh

Fraser joined Sygnature Discovery in January 2025 as Vice President, In Vivo Pharmacology. He brings 30 years of experience in high-quality research and successful project delivery across multiple therapeutic areas. Fraser has championed numerous programs into clinical development and fostered cross-functional collaboration across different drug modalities. At Sygnature, he sets strategic direction for the global in vivo pharmacology department, driving scientific and operational excellence and ensuring the highest ethical and regulatory standards. 

Fraser graduated from the University of Aberdeen with a BSc in Pharmacology.